Literature DB >> 2548877

Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2,D-Pen5]enkephalin.

J S Heyman1, J L Vaught, H I Mosberg, R C Haaseth, F Porreca.   

Abstract

The effect of the delta-selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE) on the antinociception produced by intracerebroventricular (i.c.v.) administration of the mu agonists morphine, [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAGO), [NMePhe3,D-Pro4]morphiceptin (PLO17), beta-endorphin, phenazocine, etorphine and sufentanil was studied in mice. Only the antinociceptive effects of morphine and normorphine were modulated by i.c.v. coadministration of a dose of DPDPE which did not produce any significant antinociception alone. Both the morphine and normorphine dose-response lines were displaced to the left in the presence of DPDPE. The delta-selective antagonist ICI174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH) (where Aib is alpha-aminoisobutyric acid) blocked the modulation of morphine antinociception by DPDPE. ICI 174,864 alone failed to produce either a significant increase or decrease of morphine, phenazocine, etorphine or beta-endorphin antinociception. The results of the present study provide support for the hypothesis that the enkephalins may function to modulate antinociception produced at the mu receptor; such modulation may come about via the existence of an opioid mu-delta receptor complex. The mu receptors existing in such a complex may be selectively activated by morphine and normorphine, but not the other mu agonists studied here. Thus, the enkephalins may function both to directly initiate, as well as to modulate, some forms of supraspinal mu receptor-mediated antinociception.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548877     DOI: 10.1016/0014-2999(89)90764-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.

Authors:  Ivone Gomes; Achla Gupta; Julija Filipovska; Hazel H Szeto; John E Pintar; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

Review 3.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 4.  Pharmacotherapy of opioids: present and future developments.

Authors:  T F Meert
Journal:  Pharm World Sci       Date:  1996-01

5.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

Review 6.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

7.  Effects of the delta opioid against BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure.

Authors:  S S Negus; D Morgan; C D Cook; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

8.  Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Authors:  Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby
Journal:  J Heterocycl Chem       Date:  2016-06-01       Impact factor: 2.193

9.  Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury.

Authors:  R W Hurley; D L Hammond
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

10.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.